Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Haematologica Year : 2006

Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Lionel Adès
Hervé Dombret
Agnès Guerci
  • Function : Author
  • PersonId : 762489
  • IdRef : 085731153

Abstract

We report on the outcomes of 53 patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia secondary to MDS, autografted in first complete remission. Five (9.4%) died from the procedure whereas hematological reconstitution occurred in all the remaining patients. Forty patients (75%) relapsed, with 87.5% of the relapses occurring within 2 years of the autologous transplant. With a median follow-up of 6.2 years, the median actuarial disease-free survival and overall survival were 8 and 17 months after autograft, respectively. Karyotype was the only prognostic factor for disease-free and overall survival. The eight survivors (15%), including two patients with unfavorable or intermediate karyotype, remained in first complete remission 50+ to 119+ months after transplantation and are probably cured.
Fichier principal
Vignette du fichier
373.pdf (147.59 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-00473474 , version 1 (28-12-2010)

Identifiers

  • HAL Id : inserm-00473474 , version 1
  • PUBMED : 16531261

Cite

Sophie Ducastelle, Lionel Adès, Claude Gardin, Hervé Dombret, Thomas Prébet, et al.. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.. Haematologica, 2006, 91 (3), pp.373-6. ⟨inserm-00473474⟩
370 View
283 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More